Ultragenyx Pharmaceutical

Latest news

• FDA Approves Dojolvi (triheptanoin) for the Treatment of Long-Chain Fatty Acid Oxidation Disorders
  30 June 2020
• Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)
  18 June 2020
• Ultragenyx Announces FDA Accepts New Drug Application for UX007 (triheptanoin) for Treatment of Long-chain Fatty Acid Oxidation Disorders
  14 October 2019
• FDA Approves Label Update for Crysvita (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH) in Pediatric Patients 6 Months of Age and Older
  30 September 2019
• Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders
  1 August 2019
• Ultragenyx Announces Intent to Submit New Drug Application to U.S. FDA for UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Mid-2019
  14 November 2018
• FDA Approves Crysvita (burosumab-twza) for X-Linked Hypophosphatemia
  17 April 2018
• FDA Approves Mepsevii (vestronidase alfa) for Mucopolysaccharidosis Type VII
  15 November 2017
• Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab Biologics License Application
  10 October 2017
• Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumab Biologics License Application in the US
  24 August 2017

Drugs Associated with Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. manufactures, markets and/or distributes more than 3 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.